Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2015-09-08 Regulatory Filings
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a Second Amendment to a License Agreement. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is not a transcript, proxy, or governance report. It is a regulatory announcement of a material contract amendment, which fits best under the category of Regulatory Filings (RNS) as it does not fit into more specific categories like Capital/Financing Update or M&A Activity. The document length is about 5,000 characters, and it includes the full text of the announcement, not just a notice of report publication.
2015-09-08 English
FORM 4 SUBMISSION
Director's Dealing
2015-08-26 English
FORM 4 SUBMISSION
Director's Dealing
2015-08-26 English
FORM 4 SUBMISSION
Director's Dealing
2015-08-21 English
FORM 4 SUBMISSION
Director's Dealing
2015-08-21 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a lease amendment for office space. It includes details about the lease terms, rent abatements, and tenant improvement allowance. There are no financial statements or quarterly results presented, nor is this an annual report or earnings release. The document is not a certification or a proxy statement, nor does it relate to management changes or voting results. It is a regulatory filing announcing a material contract event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is over 5,000 characters and contains substantive information, confirming it is not merely a report publication announcement.
2015-08-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.